Skip to main content

Table 2 Hotspots of gain and amplification

From: High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer

CytoBand

Start

Length

Gains (T)

nAMP (T)

Gains (CL)

nAMP (CL)

Genes

1q21.1

144.22

1.65

0.49

10

0.37

0

RBM8A, POLR3C, ZNF364

1q21.3-1q22

153.29

0.09

0.51

8

0.39

0

EFNA4, MUC1

1q23.2

157.95

0.32

0.53

10

0.39

1

DUSP23, IGSF9

1q23.3

159.23

<0.01

0.55

12

0.43

1

F11R

1q42.13-1q42.2

226.95

2.59

0.57

12

0.45

0

SPHAR, NUP133, GALNT2

1q43-1q44

240.32

4.75

0.58

11

0.45

0

SDCCAG8, ADSS, FAM36A

6q21

107.12

<0.01

0.11

5

0.02

0

AIM1

6q21

107.14

0.2

0.11

4

0.02

0

RTN4IP1, QRSL1

8p12

37.82

<0.01

0.32

16

0.24

4

GPR124, BRF2

8p12

38.04

0.1

0.32

17

0.22

3

ASH2L, LSM1

8p12

38.24

0.06

0.32

18

0.24

3

WHSC1L1

8q21.13

82.73

0.14

0.47

13

0.37

1

ZFAND1, CHMP4C

8q21.3

87.54

0.48

0.49

15

0.39

1

FAM82B, CPNE3

8q22.3

102.57

1.37

0.54

17

0.51

1

GRHL2, RRM2B, EDD1*, AZIN1*

8q22.3

104.52

<0.01

0.54

15

0.51

1

WDSOF1*

8q24.11

118.02

0.58

0.54

23

0.61

4

THRAP6*

8q24.12

120.81

0.1

0.53

23

0.57

3

DCC1*

8q24.13

124.90

1.14

0.53

22

0.65

3

TRMT12*, RNF139*, NDUFB9*

8q24.13

126.06

0.28

0.53

23

0.65

4

SQLE*, KIAA0196*

8q24.3

144.53

0.09

0.40

12

0.39

0

RHPN1, ZC3H3

9p22.3-9p22.1

16.40

2.65

0.11

1

0.12

1

C9orf39, FAM29A

10p14

12.20

0.05

0.20

2

0.18

0

NUDT5, SEC61A2

10p13

12.33

2.66

0.20

3

0.18

0

OPTN, FAM107B, SUV39H2

11q13.3

69.73

<0.01

0.17

11

0.33

2

FADD

11q13.3

69.90

<0.01

0.16

8

0.31

1

PPFIA1

11q14.1

77.01

0.38

0.12

8

0.24

3

CLNS1A, INT4

11q14.1

77.47

0.16

0.12

10

0.29

3

NDUFC2*, ALG8*, USP35*

16p13.2-16p13.13

8.78

1.68

0.38

3

0.06

0

ABAT, PMM2, USP7

16p12.3

18.44

1.21

0.39

3

0.10

0

NOMO2, ARL6IP, MIR16

17q12

33.73

<0.01

0.16

9

0.08

3

MRPL45

17q12

34.15

0.02

0.19

15

0.12

4

PSMB3

17q12

34.19

0.02

0.19

15

0.12

4

CCDC49

17q12

34.33

0.01

0.20

16

0.12

4

LASP1

17q12

34.67

0.01

0.23

23

0.12

4

FBXL20

17q12

35.06

0.02

0.27

25

0.29

11

STARD3, TCAP, PNMT

17q12

35.08

0.06

0.27

27

0.29

12

ERBB2, GRB7

17q12

35.29

0.03

0.23

21

0.27

10

GSDML

17q21.1

35.44

0.07

0.16

15

0.16

5

THRAP4, NR1D1

17q21.2

35.77

0.03

0.13

6

0.06

1

TOP2A

17q21.32

44.27

0.1

0.17

9

0.22

3

ATP5G1, UBE2Z

17q21.33

44.95

0.19

0.18

6

0.18

2

SPOP, SLC35B1

17q21.33

45.80

0.02

0.19

7

0.20

2

MRPL27, LRRC59

17q22

54.12

0.44

0.19

6

0.20

2

RAD51C, TRIM37

17q23.1

55.12

0.01

0.23

9

0.20

2

CLTC, PTRH2

17q23.1

55.38

0.1

0.23

8

0.20

3

RPS6KB1, ABC1

17q23.3

58.97

0.29

0.23

6

0.20

1

CCDC44, DDX42, FTSJ3

17q24.2

62.77

<0.01

0.24

7

0.33

1

PSMD12

17q25.1

68.72

0.03

0.22

4

0.18

0

COG1, C17orf80

17q25.1

70.52

0.03

0.17

5

0.16

0

ICT1, ATP5H

17q25.1

70.57

0.2

0.16

5

0.16

0

HN1, NUP85, MRPS7

17q25.1

71.15

0.15

0.17

4

0.16

0

ITGB4, H3F3B

20p11.23

17.97

1.51

0.25

3

0.16

0

ZNF133, RBBP9, HARS2

20q13.12

42.95

0.05

0.27

2

0.29

2

YWHAB

20q13.12

43.77

0.2

0.26

1

0.29

0

DNTTIP1, UBE2C, NEURL2

20q13.13

46.43

0.86

0.28

2

0.29

1

CSE1L, STAU1

20q13.33

60.21

0.53

0.28

3

0.31

0

HRH3, ADRM1, LAMA5

20q13.33

61.45

0.2

0.27

3

0.18

0

EEF1A2, C20orf149, PTK6

20q13.33

62.04

0.17

0.27

3

0.20

1

UCKL1, C20orf14, OPRL1

21q22.3

42.85

0.47

0.13

2

0.08

0

SLC37A1, WDR4, NDUFV3

21q22.3

46.49

0.2

0.12

2

0.06

0

MCM3AP

  1. Selected regions of frequent gain/amplification and strong coordinate overexpression. Columns give cytoband, start position (Mb), length (Mb), frequency of gains across 171 tumors (T), number of amplifications in 171 tumors (T), frequency of gains across 49 cell lines (CL), number of amplifications in 49 cell lines, selected genes in region showing strong coordinate overexpression. * denotes genes significantly associated with either overall survival, time to distant metastasis or disease free interval (p < 0.05).